Figure 4.

Re-evaluation of Javelin 101 reveals differing propensity for response by angio-immune subtypes

(A) Heatmap of Pearson correlation of 726 patients with renal cell carcinoma across 91 gene sets corresponding T cell and angiogenesis activity. Angio-immune subtypes are preserved in the renal cancer cohort.

(B) Bar graphs depicting the average enrichment of angiogenesis signatures and T cell signatures in the three angio-immune subtypes in renal cell carcinoma cohort. Enrichment of pathways was conducted using gene set variation analysis (GSVA). The enrichment of representative gene sets is plotted. One-way ANOVA was used to determine statistical significance.

(C) Progression-free survival of patients treated with sunitinib versus the combination of axitinib + avelumab.

(D) Progression-free survival of patients treated with sunitinib belonging to different angio-immune clusters.

(E) Progression-free survival of patients treated with combination of axitinib + avelumab belonging to different angio-immune clusters.

(F) Progression-free survival of patients belonging in C1 treated with sunitinib versus the combination of axitinib + avelumab.

(G) Progression-free survival of patients belonging in C2 treated with sunitinib versus the combination of axitinib + avelumab.

(H) Progression-free survival of patients belonging in C3 treated with sunitinib versus the combination of axitinib + avelumab.

∗ = p < 0.05, ∗∗ = p < 0.01, ∗∗∗ = p < 0.001, ∗∗∗∗ = p < 0.0001.